Index
1 Market Overview of Dendritic Cell Cancer Vaccine Immunotherapy
1.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Overview
1.1.1 Dendritic Cell Cancer Vaccine Immunotherapy Product Scope
1.1.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Status and Outlook
1.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2029)
1.4 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Region (2018-2023)
1.5 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
1.6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
1.6.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
1.6.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
1.6.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
1.6.5 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size (2018-2029)
2 Dendritic Cell Cancer Vaccine Immunotherapy Market by Type
2.1 Introduction
2.1.1 Provenge
2.1.2 Apceden
2.1.3 CreaVax
2.1.4 Others
2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Type (2018-2023)
2.2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Type (2018-2029)
3 Dendritic Cell Cancer Vaccine Immunotherapy Market Overview by Application
3.1 Introduction
3.1.1 Pediatrics
3.1.2 Adults
3.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Historic Market Size by Application (2018-2023)
3.2.2 Global Dendritic Cell Cancer Vaccine Immunotherapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Dendritic Cell Cancer Vaccine Immunotherapy Revenue Breakdown by Application (2018-2029)
4 Dendritic Cell Cancer Vaccine Immunotherapy Competition Analysis by Players
4.1 Global Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Dendritic Cell Cancer Vaccine Immunotherapy as of 2022)
4.3 Date of Key Players Enter into Dendritic Cell Cancer Vaccine Immunotherapy Market
4.4 Global Top Players Dendritic Cell Cancer Vaccine Immunotherapy Headquarters and Area Served
4.5 Key Players Dendritic Cell Cancer Vaccine Immunotherapy Product Solution and Service
4.6 Competitive Status
4.6.1 Dendritic Cell Cancer Vaccine Immunotherapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Lineage Cell Therapeutics
5.1.1 Lineage Cell Therapeutics Profile
5.1.2 Lineage Cell Therapeutics Main Business
5.1.3 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.1.4 Lineage Cell Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.1.5 Lineage Cell Therapeutics Recent Developments
5.2 AVAX Technologies
5.2.1 AVAX Technologies Profile
5.2.2 AVAX Technologies Main Business
5.2.3 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.2.4 AVAX Technologies Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.2.5 AVAX Technologies Recent Developments
5.3 DCPrime
5.3.1 DCPrime Profile
5.3.2 DCPrime Main Business
5.3.3 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.3.4 DCPrime Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.3.5 Gradalis Recent Developments
5.4 Gradalis
5.4.1 Gradalis Profile
5.4.2 Gradalis Main Business
5.4.3 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.4.4 Gradalis Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.4.5 Gradalis Recent Developments
5.5 Heat Biologics
5.5.1 Heat Biologics Profile
5.5.2 Heat Biologics Main Business
5.5.3 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.5.4 Heat Biologics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.5.5 Heat Biologics Recent Developments
5.6 ImmunoCellular Therapeutics
5.6.1 ImmunoCellular Therapeutics Profile
5.6.2 ImmunoCellular Therapeutics Main Business
5.6.3 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.6.4 ImmunoCellular Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.6.5 ImmunoCellular Therapeutics Recent Developments
5.7 Immunicum
5.7.1 Immunicum Profile
5.7.2 Immunicum Main Business
5.7.3 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.7.4 Immunicum Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.7.5 Immunicum Recent Developments
5.8 MolecuVax
5.8.1 MolecuVax Profile
5.8.2 MolecuVax Main Business
5.8.3 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.8.4 MolecuVax Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.8.5 MolecuVax Recent Developments
5.9 Northwest Biotherapeutics
5.9.1 Northwest Biotherapeutics Profile
5.9.2 Northwest Biotherapeutics Main Business
5.9.3 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.9.4 Northwest Biotherapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.9.5 Northwest Biotherapeutics Recent Developments
5.10 Pique Therapeutics
5.10.1 Pique Therapeutics Profile
5.10.2 Pique Therapeutics Main Business
5.10.3 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.10.4 Pique Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.10.5 Pique Therapeutics Recent Developments
5.11 Regeneus
5.11.1 Regeneus Profile
5.11.2 Regeneus Main Business
5.11.3 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.11.4 Regeneus Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.11.5 Regeneus Recent Developments
5.12 Tessa Therapeutics
5.12.1 Tessa Therapeutics Profile
5.12.2 Tessa Therapeutics Main Business
5.12.3 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.12.4 Tessa Therapeutics Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.12.5 Tessa Therapeutics Recent Developments
5.13 Vaccinogen
5.13.1 Vaccinogen Profile
5.13.2 Vaccinogen Main Business
5.13.3 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.13.4 Vaccinogen Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.13.5 Vaccinogen Recent Developments
5.14 XEME Biopharma
5.14.1 XEME Biopharma Profile
5.14.2 XEME Biopharma Main Business
5.14.3 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Products, Services and Solutions
5.14.4 XEME Biopharma Dendritic Cell Cancer Vaccine Immunotherapy Revenue (US$ Million) & (2018-2023)
5.14.5 XEME Biopharma Recent Developments
6 North America
6.1 North America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Dendritic Cell Cancer Vaccine Immunotherapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Dendritic Cell Cancer Vaccine Immunotherapy Market Dynamics
11.1 Dendritic Cell Cancer Vaccine Immunotherapy Industry Trends
11.2 Dendritic Cell Cancer Vaccine Immunotherapy Market Drivers
11.3 Dendritic Cell Cancer Vaccine Immunotherapy Market Challenges
11.4 Dendritic Cell Cancer Vaccine Immunotherapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List